Sequana Medical

Sequana Medical is a medical technology company that develops implantable and drug-based treatments for fluid overload in patients with liver disease, heart failure, and certain cancers. The company focuses on addressing cases where standard diuretic therapies are no longer effective.

The company’s main product, the alfapump®, is an implantable device that automatically transfers excess fluid from the abdominal cavity (ascites) to the bladder, where it is naturally excreted by the body. This system is designed for patients with liver disease who experience recurrent fluid build-up, helping to reduce the need for repeated hospital visits and manual fluid removal procedures.

Sequana Medical is also developing Direct Sodium Removal (DSR®) therapy, a drug-based method that aims to reduce fluid overload by removing sodium from the body. This approach is being studied primarily for patients with heart failure who are resistant to conventional diuretic treatments.

With ongoing clinical studies and regulatory development, Sequana Medical is working to expand access to its technologies and provide new options for patients with limited treatment alternatives.

Keywords: fluid overload, liver disease, heart failure, alfapump, DSR therapy, ascites treatment, implantable device, diuretic resistance, medtech, paracentesis alternative, Sequana Medical.